Evofem Biosciences Inc. has entered into a securities purchase agreement with Aditxt, Inc., involving the sale and issuance of senior subordinated convertible notes and warrants for common stock. The agreement, which closed on June 26, 2025, includes notes with an original principal amount of $1,423,076.92 and warrants to purchase 92,407,592 shares of common stock. Aditxt paid approximately $650 per $1,000 of the principal amount of the notes and warrants, resulting in net proceeds of about $925,000 for Evofem. The notes, accruing interest at 8% per annum, are convertible at $0.0154 per share and mature on June 26, 2028. The warrants are exercisable immediately at the same price per share and expire five years from issuance.